Back to Search
Start Over
Extra-mandibular Osteoradionecrosis after the Treatment of Head and Neck Cancer.
- Source :
-
Clinical Oncology . Sep2023, Vol. 35 Issue 9, pe498-e505. 8p. - Publication Year :
- 2023
-
Abstract
- Osteoradionecrosis (ORN) is a serious toxicity of head and neck radiotherapy. It predominantly affects the mandible. Extra-mandibular ORN is rare. The aim of this study was to report the incidence and outcomes of extra-mandibular ORNs from a large institutional database. In total, 2303 head and neck cancer patients were treated with radical or adjuvant radiotherapy. Of these, extra-mandibular ORN developed in 13 patients (0.5%). Maxillary ORNs (n = 8) were a consequence of the treatment of various primaries (oropharynx = 3, sinonasal = 2, maxilla = 2, parotid = 1). The median interval from the end of radiotherapy to the development of ORN was 7.5 months (range 3–42 months). The median radiotherapy dose in the centre of the ORN was 48.5 Gy (range 22–66.5 Gy). Four patients (50%) healed in 7, 14, 20 and 41 months. All temporal bone ORNs (n = 5) developed after treatment to the parotid gland (of a total of 115 patients who received radiotherapy for parotid gland malignancy). The median interval from the end of radiotherapy to the development of ORN was 41 months (range 20–68 months). The median total dose in the centre of the ORN was 63.5 Gy (range 60.2–65.3 Gy). ORN healed in only one patient after 32 months of treatment with repeated debridement and topical betamethasone cream. Extra-mandibular ORN is a rare late toxicity and this current study provides useful information on its incidence and outcome. The risk of temporal bone ORN should be considered in the treatment of parotid malignancies and patients should be counselled. More research is required to determine the optimal management of extra-mandibular ORN, particularly on the role of the PENTOCLO regimen. • Extra-mandibular osteoradionecrosis is a rare late toxicity of radiotherapy for head and neck cancer. • According to our series, the incidence is 0.5%. • Risk of temporal bone osteoradionecrosis should be considered in the radiation treatment of parotid malignancies. • More research is required to determine optimal management of extra-mandibular osteoradionecrosis. [ABSTRACT FROM AUTHOR]
- Subjects :
- *EVALUATION of medical care
*OSTEORADIONECROSIS
*MANDIBLE
*VITAMIN E
*HEAD & neck cancer
*DISEASES
*DISEASE incidence
*BETAMETHASONE
*CANCER patients
*COMPARATIVE studies
*DESCRIPTIVE statistics
*RADIATION doses
*RADIOTHERAPY
*PAROTID gland diseases
*PENTOXIFYLLINE
*DISEASE complications
MAXILLARY diseases
Subjects
Details
- Language :
- English
- ISSN :
- 09366555
- Volume :
- 35
- Issue :
- 9
- Database :
- Academic Search Index
- Journal :
- Clinical Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 169921308
- Full Text :
- https://doi.org/10.1016/j.clon.2023.06.013